What are peptides? A first-principles primer
The word "peptide" is doing a lot of work in modern wellness conversation. Some peptides are FDA-approved blockbusters with billions of dollars of clinical-trial data behind them. Some are decade-old research compounds with promising rat data and almost no human trials. Some are obscure molecules sold by gray-market vendors with quality and identity that's anyone's guess. The molecule's structure tells you something. The regulatory status and the trial evidence behind it tell you a lot more.
The structural basics
Amino acids are the building blocks of life. There are 20 standard amino acids (plus a few unusual ones), each with a unique side chain. When two amino acids join, the bond between them is called a peptide bond. A chain of two is a dipeptide; three is a tripeptide; longer is a polypeptide. By convention, "peptide" usually refers to chains of roughly 2 to 50 amino acids; longer chains are called proteins. The cutoff is conventional, not biological. Insulin (51 amino acids, two chains held together by disulfide bonds) is variously called a peptide hormone or a small protein.
The body makes peptides constantly. Hormones (insulin, glucagon, ghrelin, oxytocin, vasopressin), neuromodulators (substance P, neuropeptide Y), digestive products of food protein (most of what you absorb after a steak is small peptides and free amino acids, not whole protein), and tissue-repair signals (BPC-157 was originally isolated from gastric juice[1]) are all examples.
Synthetically manufactured peptides exploit this same vocabulary. Solid-phase peptide synthesis (Merrifield's 1963 invention, which won the Nobel Prize) lets chemists build defined sequences atom-by-atom. Modern manufacturing can produce peptides of any sequence in milligram to kilogram quantities, with quality ranging from research-grade (variable, often impure) to pharmaceutical-grade (the kind you inject into humans under regulatory oversight).[2]
What peptides do, mechanistically
Most peptide drugs work by binding receptors. Receptors are proteins on cell surfaces (or sometimes inside cells) that recognize specific shapes. A peptide whose three-dimensional structure matches the receptor's binding pocket activates that receptor's downstream signaling, which is how a chemical structure on a piece of paper translates into a clinical effect.
A few examples:
- Insulin binds the insulin receptor → activates glucose uptake and fat storage.
- Semaglutide is a modified version of GLP-1 → binds the GLP-1 receptor → slows gastric emptying, lowers glucose, suppresses appetite.[3]
- Leuprolide is a synthetic GnRH agonist → continuously stimulates the pituitary GnRH receptor → causes desensitization and ultimately suppression of testosterone or estrogen (used in prostate cancer, endometriosis, IVF protocols, gender-affirming care).[4]
- BPC-157 is hypothesized to interact with multiple tissue-repair pathways including angiogenesis, nitric oxide, and growth-factor signaling — though the mechanism is less well-characterized in humans than in rats.[5] for the mechanistic claims in humans.
A peptide's selectivity comes from its sequence and shape. Get the sequence right and you can hit a single receptor cleanly. Get it slightly wrong and you can activate related receptors with different downstream effects (sometimes a feature: tirzepatide deliberately activates both GLP-1 and GIP receptors). The art of peptide drug design is partly tuning this selectivity.
Why peptides are pharmacologically interesting
A few features make peptides distinctive:
Selectivity. Compared to small-molecule drugs, peptides can be highly selective for a single receptor or signaling pathway. This often translates to fewer off-target side effects.
Mimicry of natural signaling. Many peptide drugs are modified versions of natural hormones (semaglutide is GLP-1 with a fatty-acid tail for longer half-life; tirzepatide is engineered to bind both GLP-1 and GIP receptors). The body recognizes the structure, the downstream effects are well-mapped.
Short half-life as a feature. Many peptides are cleared from circulation within minutes to hours of administration. This is sometimes a drawback (requires frequent dosing) and sometimes a feature (limits long-term exposure if something goes wrong).
Oral bioavailability is usually terrible. Stomach acid and digestive enzymes break peptides down into amino acids, which is why insulin, GLP-1s, and most other peptide drugs require injection or specialized delivery (oral semaglutide exists but requires a permeation enhancer and has lower absorption than injectable). This is also why "peptide collagen for joints" claims are mostly nonsense — the peptide is digested before it can do anything systemically.
The regulatory landscape that the wellness world ignores
Here is where most peptide conversations go off the rails.
FDA-approved peptides are real drugs. They've been through preclinical safety, Phase 1 (safety in humans), Phase 2 (preliminary efficacy), and Phase 3 (large RCT efficacy and safety) trials, plus post-market surveillance. Examples include insulin (a century of use), GnRH agonists, GLP-1 receptor agonists, tesamorelin (HIV-associated lipodystrophy), and dozens of others. These are subject to the same pharmacovigilance as any prescription drug.
Compounded peptides are a gray area. Compounding pharmacies can legally prepare custom peptide preparations when there's a documented clinical reason, under state and federal oversight. The quality varies. The FDA has, in recent years, restricted what compounding pharmacies can sell — semaglutide compounding was substantially curtailed once the shortage ended.
Research-only peptides are the largest gray zone. Companies sell BPC-157, TB-500, MOTS-c, epitalon, melanotan II, and dozens of others under labels that explicitly say "not for human consumption" — a legal shield that lets them avoid FDA oversight while users in fact inject the compounds. Quality, purity, identity, and sterility are not guaranteed in this market. Many of these compounds have never been tested in humans under any FDA framework.
A clear way to think about this: when you read "peptide therapy" in marketing copy, the first question is which kind of peptide. Insulin and GLP-1 receptor agonists are drugs you can stake a clinical practice on. BPC-157 from an online vendor is a category of decision the FDA has not blessed and the human evidence has not yet established.
How to think about any peptide claim
Three questions to ask of any peptide piece you read:
- Is there a human randomized controlled trial? For many of the buzziest peptides (BPC-157, TB-500, MOTS-c, epitalon) the answer is no, or only one small trial. Rat data and human anecdote are not the same as RCT evidence.
- Who funded the research, and what are they selling? Many peptide-promoting articles cite studies done by, or funded by, companies that profit from peptide sales. The same skepticism that applies to industry-funded supplement studies applies here.
- What's the regulatory status? Is this an FDA-approved drug being used on-label (well-studied territory), an FDA-approved drug used off-label (sometimes reasonable, sometimes speculative), or a research-only compound with no human approval (the deepest uncertainty)?
The peptide field has real frontiers. GLP-1s are reshaping obesity medicine. Tesamorelin works for a specific clinical population. Some of the more speculative peptides may eventually be vindicated by trials, others may not. The honest position is to know which category each peptide is in, and to weight the evidence accordingly.
FAQ
Peptide vs protein? Length. Peptides are short chains (≤50 amino acids by convention); proteins are longer. Functionally the line is fuzzy.
Is a peptide a drug? Sometimes. FDA-approved peptides are drugs. Research-grade peptides are not, regardless of who's selling them.
Why now? GLP-1s are blockbusters. Synthesis costs are down. Longevity research focused attention on multiple peptide classes. The interest is partly real, partly marketing overshoot.
References
- 1.Sikiric P, et al. (2018). Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World Journal of Gastroenterology 24(46):5197–5209. PMID: 30581268. Link
- 2.Lau JL, Dunn MK (2018). Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry 26(10):2700–2707. PMID: 28720325. Link
- 3.Wilding JPH, et al. (STEP 1 Study Group) (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 384(11):989–1002. PMID: 33567185. Link
- 4.Conn PM, Crowley WF (1991). Gonadotropin-releasing hormone and its analogues. New England Journal of Medicine 324(2):93–103. PMID: 1984190. Link
- 5.Chang CH, et al. (2011). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 16(3):2107–2118. PMID: 21368728. Link
This article is for educational purposes only and is not medical advice. It is not a substitute for professional diagnosis, treatment, or the guidance of a qualified clinician. Always consult your physician before changing your diet, starting a fast, taking supplements, or beginning a new training or heat/cold protocol, especially if you are pregnant, breastfeeding, managing a medical condition, or taking medication.